(secondQuint)Safety, Tolerability, Pharmacokinetics & Pharmacodynamics Study of Ropeginterferon Alfa-2b in Healthy Japanese and Caucasian Subjects.

 Twenty-four healthy eligible Japanese male subjects and 24 healthy eligible Caucasian male subjects, each divided into 4 cohorts of 6 subjects, will participate in this study.

 No subject will participate in more than 1 cohort and all subjects will receive a single dose of P1101.

 Caucasian subjects will be body weight- and height-matched to Japanese subjects.

 Dosing will be initiated with the lowest dose of 100 1/2g in both Japanese and Caucasian subjects.

.

 Safety, Tolerability, Pharmacokinetics & Pharmacodynamics Study of Ropeginterferon Alfa-2b in Healthy Japanese and Caucasian Subjects@highlight

This is a Phase 1 single center, parallel group study to assess and compare the safety, tolerability, PK and PD of 4 single ascending doses of P1101 (100, 200, 300, and 450 1/2g) following subcutaneous administration in healthy Japanese and Caucasian subjects.

